Due to health issues, this site is no longer maintained and will be shut down shortly.

TCBPW TC BioPharm (Holdings) plc Warrants

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its products pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; ImmuniStim, an unmodified cell therapy to treat COVID-19; TCB009 for the GI-tract cancer treatment; and TCB005/TCB006 that are allogeneic co-stimulatory GD-T CAR pre-clinical drug candidates would target antigens expressed on various solid tumor types. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.  This security was issued by TC BioPharm (Holdings) plc ADRs, whose common stock symbol is TCBP.

$0.09  0.00 (0.00%)
As of 03/24/2023 00:00:00 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Warrants
Category3:  Operating Companies
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  United Kingdom
Country of incorporation:  
IPO date:  02/08/2022
Outstanding shares:  7,529,412
Average volume:  40,481
Market cap:   $2,194,403
Current dividend yield:  0.00%
All SEC filings:   SEC Edgar Online
Annual filings:      20-F

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy